Author

Edward Michael Chan

Observed names: E. Chan, E. M. Chan, E. Michael Chan, Edward Chan, Edward M Chan, Edward M. Chan, Edward m Chan

Observed institutions: Scripps Research Institute, National Institutes of Health, City Of Hope National Medical Center, Amgen (United States), Eli Lilly (United States), University of New Mexico, Pfizer (United States), Genentech, UNSW Sydney, National Institute of Diabetes and Digestive and Kidney Diseases, Yuma Oncology Center, Eli Lilly (Spain), Arvinas (United States), Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, UNM Comprehensive Cancer Center, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis

ORCID: 0000-0002-1332-2987

Observed ORCID: 0000-0002-1332-2987

OpenAlex ID: A5083329029

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

2016 · Amita Patnaik, Lee S. Rosen, et al. · Cancer Discovery · 741

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

2014 · Lawrence M. Gelbert, Shufen Cai, et al. · Investigational New Drugs · 572

PDF

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

2023 · Nizar J. Bahlis, Caitlin L. Costello, et al. · Nature Medicine · 161

PDF

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

2014 · Vipin Yadav, Teresa F. Burke, et al. · Molecular Cancer Therapeutics · 132

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

2015 · Amita Patnaik, Paul Haluska, et al. · Clinical Cancer Research · 131

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

2014 · Sonya C. Tate, Shufen Cai, et al. · Clinical Cancer Research · 129

PDF

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

2013 · Robert M. Campbell, Bryan D. Anderson, et al. · Molecular Cancer Therapeutics · 118

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

2016 · Shubham Pant, Suzanne F. Jones, et al. · European Journal of Cancer · 92

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

2017 · Sonya C. Tate, Amanda K. Sykes, et al. · Clinical Pharmacokinetics · 71

PDF

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

2013 · Geoffrey Shapiro, Lee S. Rosen, et al. · Journal of Clinical Oncology · 66

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

2016 · Yutaka Fujiwara, Kenji Tamura, et al. · Cancer Chemotherapy and Pharmacology · 61

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

2021 · Michael Sebag, Noopur S. Raje, et al. · Blood · 54

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

2024 · Daniel P. Petrylak, Meredith McKean, et al. · Journal of Clinical Oncology · 51

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

2022 · Noopur Raje, Nizar Jacques Bahlis, et al. · Blood · 46

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

2021 · Nizar J. Bahlis, Noopur S. Raje, et al. · Journal of Clinical Oncology · 44

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

2018 · Robert Hans Ingemar Andtbacka, Reinhard Dummer, et al. · Journal of Clinical Oncology · 42

Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

2014 · Amita Patnaik, Lee S. Rosen, et al. · Cancer Research · 42

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.

2014 · Amita Patnaik, Lee S. Rosen, et al. · Journal of Clinical Oncology · 42

A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2023 · Daniel P. Petrylak, Tyler F. Stewart, et al. · Journal of Clinical Oncology · 41

429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

2020 · Georgina Long, Reinhard Dummer, et al. · Regular and Young Investigator Award Abstracts · 35

MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB–dependent promoters

2007 · Edward M. Chan, Rebecca J. Chan, et al. · Experimental Hematology · 35

AML1-FOG2 fusion protein in myelodysplasia

2005 · E. M. Chan · Blood · 32

Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating PTPN11 Mutants

2009 · Zhenyun Yang, Takako Kondo, et al. · Molecular and Cellular Biology · 31

A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

2015 · Sara M. Tolaney, Muralidhar Beeram, et al. · Journal of Clinical Oncology · 28

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.

2014 · Jonathan Wade Goldman, Leena Gandhi, et al. · Journal of Clinical Oncology · 27

Works count: 93

Citation count: 3,004

H-index: 25

I10-index: 34